Oncology News | pharmaphorum

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

MSD buys Modifi for $1.3bn to boost oncology pipeline

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

News

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers.

News

Foundation stone ceremony at Orano Med's ATLab plant in France, set to be the first industrial-scale pharma facility in Europe for lead-212 isotopes

Sanofi invests €300m in Orano Med's lead-based radioligands

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

News

Head and neck cancer trials 'becoming less diverse'

Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD buys Modifi for $1.3bn to boost oncology pipeline

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

Sanofi invests €300m in Orano Med's lead-based radioligands

NICE backs first targeted therapy for ALK+ lung cancer

Head and neck cancer trials 'becoming less diverse'

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks